Loading...
•
Jun 30, 2025
Puma Biotechnology Q2 2025 Earnings Report
Puma Biotechnology reported strong financial results for the second quarter of 2025, driven by increased NERLYNX® sales and a significant improvement in net income compared to the previous year.
Key Takeaways
Puma Biotechnology delivered a robust performance in Q2 2025, with total revenue reaching $52.4 million, up from $47.1 million in Q2 2024. The company achieved a net income of $5.9 million, a substantial turnaround from a net loss of $4.5 million in the same period last year. This positive shift was primarily fueled by increased product revenue from NERLYNX® and reduced selling, general, and administrative expenses.
Total revenue for Q2 2025 increased to $52.4 million, up from $47.1 million in Q2 2024, primarily due to higher product and royalty revenue.
The company reported a net income of $5.9 million ($0.12 per share) in Q2 2025, a significant improvement from a net loss of $4.5 million ($0.09 per share) in Q2 2024.
Non-GAAP adjusted net income for Q2 2025 was $7.5 million ($0.15 per share), compared to a non-GAAP adjusted net loss of $2.5 million ($0.05 per share) in Q2 2024.
Net cash provided by operating activities saw a substantial increase to $14.1 million in Q2 2025, up from $1.0 million in Q2 2024.
Revenue by Segment
Forward Guidance
Puma Biotechnology provided a positive financial outlook for Q3 and Full Year 2025, anticipating continued revenue growth and net income.
Positive Outlook
- Projected Q3 2025 net product revenue of $46-$48 million.
- Anticipated Q3 2025 total revenue of $48-$51 million.
- Forecasted Full Year 2025 total revenue of $212-$222 million.
- Expected Full Year 2025 net income of $23-$28 million.
- Anticipated presentation of interim data from ALISCA™-Breast1 Phase II trial in Q4 2025.
Challenges Ahead
- No license revenue is projected for Q3 or Full Year 2025.
- The outlook does not include any adjustments for tax valuation allowance.
- Gross to Net Adjustment for Full Year 2025 is projected to be 21.5%-22.0%, an increase from the previous year's 20.5%-21.5%.
- Interest income is projected to decrease compared to the previous year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...